MyMD Pharmaceuticals to Discuss its Novel Therapies for Aging and Related Diseases at the Dawson James Securities sixth Annual Small Cap Growth Conference on October 21
MyMD is seeking after high worth freedoms in a gigantic medical care market with no known contending FDA-supported medications for treating maturing messes and broadening solid life expectancy
MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage drug organization focused on broadening solid life expectancy, declared today that it will introduce at the Dawson James Securities sixth Annual Small Cap Growth Conference on Thursday, October 21, 2021, at 4:30 p.m. ET in Track 1. The gathering is being held at the Wyndham Grand Jupiter at Harbourside Place in Jupiter, Florida.
MyMD Chief Scientific Officer Adam Kaplin, M.D., Ph.D. will examine the various signs for every one of MyMD’s clever medication up-and-comers, MYMD-1 and Supera-CBD. A webcast of the show will be accessible live and on interest for 90 days after the gathering.
This portion as of now represents a 10.4% portion of the worldwide Automated and Rapid Microbiological Tests market. The flood in the events of STDs, like GC/Chlamydia, HIV and Syphilis, has transformed STD fast tests into the most powerful and incredible section of the market.
About MYMD-1
MYMD-1’s main role is to slow the maturing system and broaden solid life expectancy, and it is likewise showing guarantee as a possible treatment for post-COVID-19 entanglements and as an enemy of fibrotic and hostile to productive restorative. MYMD-1 has shown adequacy in directing the resistant framework by proceeding as a specific inhibitor of cancer rot factor-alpha (TNF-α), a driver of constant aggravation. In contrast to different treatments, MYMD-1 has been displayed to specifically obstruct TNF-α when it becomes overactivated in immune system sicknesses and cytokine storms, yet not block it from doing its ordinary occupation of being a person on call for any normal sort of moderate contamination. MYMD-1’s simplicity of oral dosing is one more differentiator contrasted with presently accessible TNF-α blockers, all of which require conveyance by infusion or imbuement. No endorsed TNF inhibitor has at any point been dosed orally. Furthermore, the medication isn’t immunosuppressive and has not been displayed to cause the genuine incidental effects normal with customary treatments that treat irritation. MyMD hopes to dispatch two Phase 2 preliminaries during the current quarter for MYMD-1 – one for deferring maturing and dragging out solid life expectancy, and the other for post-COVID-19 discouragement and cytokine height.
About Supera-CBD
Supera-CBD is MyMD’s pre-clinical protected engineered cannabidiol (CBD) subsidiary that is being created as a drug medication to address tension, torment, and neurodegeneration. Supera-CBD focuses on the cannabinoid receptor type 2 (CB2), a protein primarily communicated in the safe framework and which is related with the helpful impacts of CBD, including its anxiolytic, anticonvulsant, antipsychotic, neuroprotective and mitigating properties. CB2 receptors don’t make an inebriating negative psychotropic response (for example a high). Conversely, CB1 is normally communicated in the mind and dispersed all through the focal sensory system to convey an inebriating impact. A larger part of CBD designers are seeking after compounds designated to CB2 that have insignificant CB1 proclivity. MyMD’s Supera-CBD, with low CB1 liking and four-crease expanded CB2 restricting, is multiple times more strong a CB2 agonist (activator) than normal CBD. The Company accepts that Supera-CBD is as of now on a way toward human clinical preliminaries as a treatment for epilepsy, trailed by ongoing agony.
About MyMD Pharmaceuticals, Inc.
MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD), a clinical stage drug organization focused on broadening sound life expectancy, is centered around creating two novel helpful stages that treat the reasons for sickness as opposed to just tending to the indications. MYMD-1 is a medication stage dependent on a clinical stage little atom that directs the safe framework to control TNF-α, which drives persistent aggravation, and other favorable to provocative cell flagging cytokines. MYMD-1 is being created to defer maturing, increment life span, and treat immune system infections and COVID-19-related wretchedness. The Company’s second medication stage, Supera-CBD, is being created to treat constant torment, habit and epilepsy. Supera-CBD is an original engineered subsidiary of cannabidiol (CBD) and is being created to address and develop the quickly developing CBD market, which incorporates both FDA endorsed medications and CBD items not presently controlled as medications. For more data,
Preventative Statement Regarding Forward-Looking Statements
This official statement might contain forward-looking proclamations. These forward-looking assertions imply known and obscure dangers, vulnerabilities and different variables which might cause real outcomes, execution or accomplishments to be substantially not the same as any normal future outcomes, execution, or accomplishments. Forward-looking explanations talk just as of the date they are made and none of MyMD nor its members accept any obligation to refresh forward-looking proclamations. Words, for example, “expect,” “accept,” “could,” “gauge,” “anticipate,” “may,” “plan,” “will,” “would” and other comparative articulations are planned to recognize these forward-looking assertions. Significant elements that could make genuine outcomes vary substantially from those demonstrated by such forward-looking explanations incorporate, without impediment: the circumstance of, and MyMD’s capacity to, acquire and keep up with administrative endorsements for clinical preliminaries of MyMD’s drug up-and-comers; the circumstance and consequences of MyMD’s arranged clinical preliminaries for its drug competitors; the measure of assets MyMD needs for its drug applicants; expanded degrees of rivalry; changes in political, financial or administrative conditions by and large and in the business sectors where MyMD works; MyMD’s capacity to hold and draw in senior administration and other key representatives; MyMD’s capacity to rapidly and successfully react to new mechanical turns of events; MyMD’s capacity to ensure its proprietary advantages or other restrictive privileges, work without encroaching upon the exclusive freedoms of others and keep others from encroaching on MyMD’s restrictive freedoms; and the effect of the continuous COVID-19 pandemic on MyMD’s aftereffects of tasks, strategy and the worldwide economy. A conversation of these and different elements as for MyMD is gone ahead in the Quarterly Report on Form 10-Q for the quarterly time frame finished June 30, 2021, recorded by MyMD on August 16, 2021. Forward-looking proclamations talk just as of the date they are made and MyMD renounces any aim or commitment to reexamine any forward-looking assertions, regardless of whether because of new data, future occasions or in any case
